Process RAG query

{
    "data": {
        "answer": "Management at Novo Nordisk emphasized strategic goals focused on purpose, sustainability, expanding patient reach, developing superior treatment solutions for obesity, and commercial execution. They highlighted their commitment to serving more than 45 million patients, capacity expansion, and ongoing R&D milestones, particularly in obesity treatments like cagrisema and semaglutide. They also stressed maintaining market leadership in GLP1 treatments, expanding manufacturing capacity, and supporting growth outlooks for 2025.\n\nCompared to previous quarters, the management's emphasis on these strategic priorities remains consistent, with continued focus on scaling operations, advancing R&D, and expanding patient access. The recent quarter's performance highlights solid commercial execution and growth, reinforcing their ongoing strategic aspirations.",
        "sources": [
            {
                "text": "And Head of Commercial Strategy and Corporate Affairs, Camilla Silvest, Executive Vice President, US Operations and Head of Global Business Development, Dave Moore, Executive Vice President and Head of Development Martin Holz Lange and finally Chief Financial Officer Karst Munch Knudsen. All speakers will be available for the Q and A session. Today's announcement and the slides for this call are available on our website novonordisk.com Please note that the call is being webcast live and the recording will be made available on our website as well. The call is scheduled to last 1 hour and 15 minutes. Please turn to the next slide. The presentation is structured as outlined on slide 2. Please note that all sales and operating profit growth statements will be at constant exchange rates unless otherwise specified. Please turn to the next slide. We need to advise you that this call will contain forward looking statements. These are subject to risks and uncertainty that could cause actual results to differ materially from expectations. For further information on risk factors, please see the company announcement for the full year of 2024 and the slides prepared for this presentation. With that, over to JULAS for an update on our strategic aspirations. Thank you Jaro. Next slide please. In 2024 we delivered 26% sales growth and 26% operating profit growth. I'd like to start this call by going through the performance highlights across our strategic aspirations before handing over the word to my colleagues. Starting with our focus on purpose and sustainability, we are now serving more than 45 million patients with our diabetes and obesity treatments. This is an increase of almost 4 million patients compared to last year and reflects our continued capacity expansion efforts. Our total carbon emissions rose by 23% compared to 2023. This was mainly driven by our increased production volumes and increased investments in capital expenditure to meet the high demand for our innovative treatments. To uphold our commitment of being a sustainable employer, we expanded the number of women in senior leadership positions to 42% compared to around 41% last year. In R and D. We had several exciting obesity readouts this quarter, such as cagrisema, semaglutide, 7.2 milligrams and amocretin. These results reinforce our strategic aspiration of developing superior treatment solutions for people living with obesity. For cacliscema, we remain confident in its potent biology and look forward to further exploring its potential and to making it available to patients. Martin will come back to this and overall R&D milestones later. The quarterly sales growth reflects solid commercial execution across both operating units. Camilla and Dave will go through the details later. Carsten will go through the financial details, but I'm pleased with the sales growth of 26% in 2024 as well as an attractive growth outlook for 2025. Now I would like to hand over the word to Camilla for an update on commercial execution in 2024. Thank you Lars and please turn to the next slide. In 2024 our total sales increased by 26%. The sales growth was driven by both operating units with North America operations growing 30% and international operations growing 19%. In the US sales growth was positively impacted by gross to net sales adjustments. Our GLP1 sales in diabetes increased by 22% driven by North America operations growing 23% and international operations growing 18%. Insulin sales increased by 17% driven by North America operations growing 52%, positively impacted by gross to net sales adjustments and international operations growing 6%. Obesity care sales increased 57% driven by North America operations growing 45% and international operations growing 107%. In both geographies, growth was driven by Wegovy, partly offset by declining sex center sales. As the obesity care market is moving towards once weekly treatments, Rare disease sales increased by 9% driven by a 20% increase in North America operations and rare disease sales in international operations remained unchanged compared to last year. Please turn to the next slide. I would like to reiterate our commitment to continue reaching more patients with our innovative treatments. Today Novo Nordiskk is the global GLP1 volume market leader serving nearly two thirds of all patients on GLP1 treatments across diabetes and obesity. Our ongoing scaling efforts have supported an almost tripling of GLP1 patient reach over the last three years. In December 2024 we announced that the acquisition of the Catalan sites from Novo holdings was completed. This transaction supports our ongoing scaling efforts and will expand Novo Nordisk global fill and finish footprint from 11 to 14 sites. We still expect the three sites to gradually increase market supply beyond our pre existing CMO contracts to the market from 26 and allow us to reach significantly more patients in the years to come. Please turn to the next slide. Within Diabetes care Sales growth was 20% driven by our GLP1 portfolio and insulins. We sustained our diabetes value market share leadership with a unchanged market share of 33.7% compared to last year. This remains above our strategic aspiration of reaching 1/3 of the global diabetes value market in 2025. Please turn to the next slide. In international operations, Diabetes care sales increased by 12% in 2024 which was mainly driven by GLP1 diabetes care sales growing 18%. Novo Nordiskk remains the market leader in International operations with a GLP1 diabetes value market share of almost 64%. And with that I would hand over the word to Dave. Thank you, Camilla. Please turn to the next slide. Sales of GLP1 diabetes care products in the US increased by 24%. The sales increase was mainly driven by the continued uptake of ozempic and the GLP1 class growth. Novo Nordisk remains the market leader in the US with more than 52% market share measured by total monthly prescriptions. Please turn to the next slide. Wegovy sales increased by 86% globally, driven by a 59% growth in North America operations. And Wegovy sales in international operations have reached more than 11 billion Danish",
                "symbol": "NVO",
                "company": "NOVO NORDISK",
                "date": "2025-02-05T13:38:55Z",
                "similarity": 0.7255577
            }
        ]
    },
    "message": "Query processed successfully"
}